fluvastatin / Generic mfg. - LARVOL DELTA

Fluvastatin enhances healing of medication-related osteonecrosis of the jaw (MRONJ) via macrophage polarization in a rat MRONJ-like model. (PubMed, J Dent Sci) - "Two groups received zoledronic acid (ZOL) and dexamethasone (DEX) for two weeks prior to extraction of maxillary first molars. The ZOL/DEX group showed a predominance of pro-inflammatory M1 macrophages, whereas the FS-treated group exhibited relatively increased proportions of tissue-reparative M2 macrophages. Local FS administration enhances bone healing of MRONJ-like lesions by promoting macrophage polarization toward M2 phenotype."

Journal • Preclinical • Dyslipidemia • Metabolic Disorders

Targeting cholesterol-dependent Piezo1 activation impairs amoeboid migration in melanoma cells. (PubMed, Proc Natl Acad Sci U S A) - "Statins, including Fluvastatin, suppress amoeboid migration of melanoma cells in confined environments by reducing intracellular cholesterol...Notably, high cholesterol biosynthesis enzyme levels correlate with reduced patient survival in melanoma. These findings reveal that cholesterol is essential for confinement sensing through Piezo1, identifying cholesterol biosynthesis or uptake as rational therapeutic targets against metastasis."

Journal • Melanoma • Oncology • Solid Tumor

Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line. (PubMed, Biol Pharm Bull) - "Treatment with simvastatin, atorvastatin, and fluvastatin reduced RD cell viability in a concentration-dependent manner. Tamoxifen, a clinically available drug with PKC inhibitory activity, including against the δ isoform, attenuated simvastatin-induced cell injury, paralleling the effects of BIM. Collectively, our findings demonstrate that PKCδ contributes to statin-induced cytotoxicity in rhabdomyosarcoma cells, at least in part by regulating MCT4 expression."

Journal • Preclinical • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor

The HMG-CoA Reductase Inhibitor Fluvastatin Promotes Th2-Skewed Immune Responses by Modulating Dendritic Cell Differentiation. (PubMed, Genes Cells) - "This effect was not shared by rosuvastatin, suggesting that lipophilicity-dependent cellular uptake influences immunomodulatory potency. These functional changes were accompanied by alterations in DC surface molecule expression, although their causal contribution remains to be established. These findings indicate that continuous fluvastatin exposure during DC differentiation is associated with an altered DC phenotype and enhanced Th2-polarizing capacity."

Journal • CD4 • CSF2 • IFNG • IL4

A multicohort machine-learning prognostic signature reveals inflammatory immune remodeling and statin sensitivity in glioblastoma. (PubMed, Front Oncol) - "Simvastatin and fluvastatin were identified as potential therapeutic candidates for high-risk patients. PMLS may provide a robust platform for prognostic stratification, biological interpretation, and the development of precision-treatment strategies for patients with GBM."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects. (PubMed, Endocrinol Diabetes Metab) - "Atorvastatin, simvastatin and rosuvastatin possess the most pronounced diabetogenic properties. In contrast, lovastatin, fluvastatin, pitavastatin and most notably pravastatin exert either neutral or advantageous effects with respect to glucose metabolism."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CDC42 • RAC1

Fluvastatin Plus Dipyridamole Suppresses Canine Hemangiosarcoma Growth in Patient-Derived Xenograft Models Through Lactate Dehydrogenase-Associated Cholesterol/Lipid Metabolism. (PubMed, Vet Comp Oncol) - "In contrast, combined fluvastatin and dipyridamole treatment inhibited proliferation in vitro and tumour growth in PDX models. Collectively, these results suggest a context-dependent association between LDH and cholesterol/lipid metabolism in canine HSA cell lines and provide a rationale for further evaluation of combined cholesterol pathway inhibition."

Journal • Preclinical • Angiosarcoma • Gene Therapies • Metabolic Disorders • Oncology • Sarcoma • Solid Tumor • Transplantation • LDHA • LDHB • SREBF2

Rifampin-induced fluvastatin toxicity: a case report and review of literature. (PubMed, Oxf Med Case Reports) - "While this report is the first to describe a clinical outcome of this interaction, multiple pharmacokinetic studies have demonstrated opposing, time-dependent rifampin effects on statin concentrations. Safe management of this challenging interaction includes statin dose reduction and/or separate administration upon rifampin initiation until the anticipated onset of CYP induction, followed by careful and gradual dose titration with monitoring of both effectiveness and toxicity."

Journal • Addiction (Opioid and Alcohol) • Hepatology • Infectious Disease • Metabolic Dysfunction-Associated Steatohepatitis • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CYP2C9

Older Statins Reduce Metastatic Potential in ccRCC: Mechanistic Validation of SIM (Selective Inhibitor of Metastasis) Development (KCRS 2026) - "Statins were classified as older (fluvastatin, simvastatin, lovastatin) or newer (atorvastatin, pravastatin, rosuvastatin)...These findings support further development of SIMs towards achieving metastasis-preventive therapy for ccRCC. Keywords statin, cancer metastasis, ccRCC, selective inhibitor of metastasis DOD CDMRP Funding yes"

Metastases • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Renal Cell Carcinoma • Solid Tumor • HIF1A

Transcriptomic Identification of Diagnostic Biomarkers for Alcohol-Associated Liver Cirrhosis: Integration of Population-Level Epidemiology with Multi-Cohort Transcriptomic Analysis. (PubMed, Int J Mol Sci) - "Fluvastatin and honokiol were identified as candidate therapeutic agents, with strong binding affinities to IL1B and CCL3, respectively. This study confirms a dose-dependent alcohol-cirrhosis association and establishes a five-gene diagnostic signature (distinguishing ALC from normal liver tissue) alongside candidate therapeutics, warranting prospective clinical validation. The identified tissue-derived signature and therapeutic candidates provide a foundation for future ALC-specific diagnostic and therapeutic strategies; their translation into a non-invasive (e.g., blood-based) assay will require dedicated validation in circulating samples."

Biomarker • Journal • Addiction (Opioid and Alcohol) • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • CCL3 • IL1B • ITGA6 • SPP1

Drug repurposing of fluvastatin as a DP2 antagonist: an ensemble learning strategy with in vitro cellular functional validation. (PubMed, RSC Med Chem) - "Pitavastatin demonstrated inadequate activity at non-toxic concentrations, and levocabastine's inhibition was not concentration-dependent, precluding the determination of its IC50. Additionally, SHAP interpretability offers actionable insights into structure-activity relationships for lead optimization. In this study, the developed workflow demonstrates effective performance in the discovery of DP2 antagonists, offering a valuable reference for AI-driven drug repositioning targeting this receptor."

Journal • Preclinical • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Ultrasound-responsive nanodroplets activate the Hippo pathway via ROS-MST1-YAP cascade for breast cancer therapy. (PubMed, Ultrason Sonochem) - "Here, we report for the first time the albumin-based, ultrasound-responsive nanodroplets (FLU-NDs) encapsulating fluvastatin (FLU) to achieve accurate and targeted Hippo pathway reprogramming for efficient tumor suppression...Using this previously unrecognized UTMD-associated Hippo modulation strategy, FLU-NDs induce robust apoptosis, reverse EMT, and significantly inhibit tumor growth and metastasis in vitro and in vivo. Collectively, this study establishes a novel, high-efficacy and low-toxicity theranostic platform for precise Hippo-targeted cancer therapy."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

QbD-guided development and in silico, in vitro, ex vivo, and in vivo dermatokinetic evaluation of a fluvastatin-loaded transferosomal hydrogel for the management of melanoma. (PubMed, Biomater Adv) - "An in vitro skin irritation study portrayed the safety of the developed nanoformulation for further preclinical and clinical applications. Overall, these findings highlighted the potential of transdermal nanoformulation as a non-invasive, effective, and patient-friendly approach for melanoma management."

Journal • Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor

Fluvastatin-loaded chitosan-coated transfersomes for tumor-targeted nanotheranostics: Optimization, in-vitro cytotoxicity, and in-vivo radiokinetic evaluation. (PubMed, Nanomedicine) - "Enhanced cytotoxicity was confirmed in both tested breast cancer cell lines. These findings suggest that chitosan-coated FLU-TFs represent a promising platform for targeted drug delivery and radiokinetic imaging in solid tumors, though further validation in breast cancer-specific in-vivo models is required."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor

Clinical characteristics, diagnosis and prognosis of statin-induced acute pancreatitis. (PubMed, Intern Emerg Med) - "Statin-induced pancreatitis has a class effect that may be independent of duration or dosage. Clinicians should be aware of the possibility of statin-induced acute pancreatitis in order to facilitate early diagnosis and management."

Journal • Pain • Pancreatitis

Supramolecular nanomedicine reprogramming calcium ions metabolism for cancer cell PANoptosis and immunotherapy. (PubMed, Sci Bull (Beijing)) - "Herein, we engineer a supramolecular nanomedicine based on reduced human serum albumin co-encapsulating fluvastatin and resveratrol as dual Ca2+ metabolic modulators (RH-Flu-Res)...Results demonstrate that RH-Flu-Res achieves exceptional tumor suppression in multiple oral models, accompanied by marked PANoptosis and robust antitumor immune responses. This study identifies mtCX43 as a Ca2+-dependent molecular switch regulating PANoptosis and establishes a novel paradigm for PANoptosis-based cancer therapy via supramolecular nanomedicine-mediated Ca2+ metabolic reprogramming."

Journal • Metabolic Disorders • Oncology

Solvent-Controlled Divergent Catalysis toward the Synthesis of Fluvastatin Analogs. (PubMed, Org Lett) - "The method shows broad scope and functional group tolerance. Mechanistic studies indicate a solvent-driven switch between β-hydride elimination and protodemetalation, providing rapid access to both enantiomeric series of fluvastatin-inspired scaffolds."

Journal

KRT18 promotes the high-grade meningioma proliferation by interacting with LDHA to activate glycolysis and the PI3K/AKT signaling pathway. (PubMed, Cancer Lett) - "It also functions as an oncogene by activating glycolysis and the PI3K/AKT signaling pathway through interaction with LDHA. Additionally, Fluvastatin is identified as a candidate for drug repurposing in high-grade meningioma."

Journal • Brain Cancer • CNS Tumor • Meningioma • Oncology • Solid Tumor • Targeted Protein Degradation • KRT18 • KRT18 • LDHA

Drugs for hypercholesterolemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Metabolic Disorders

Early mortality and hospitalization following cholangiocarcinoma diagnosis by statin exposure: A TriNetX real-world analysis. (ASCO 2026) - "Patients were classified based on exposure to statins (rosuvastatin, simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, or pitavastatin) within a prespecified temporal window relative to cancer diagnosis, with the index event defined accordingly... In this real-world, propensity score–matched analysis of patients with cholangiocarcinoma, statin exposure was not associated with improved 30-day survival and was associated with higher 90-day mortality and hospitalization. Although causality cannot be inferred, these findings highlight clinically meaningful early outcome differences during the peri-diagnostic period and suggest that commonly prescribed cardiovascular medications may identify patients with increased baseline vulnerability at the time of cancer diagnosis. Future work integrating medication exposure with comorbidity burden, treatment patterns, and early care trajectories may help refine risk stratification during initial cholangiocarcinoma..."

Clinical • Real-world • Real-world evidence • Ampulla of Vater Carcinoma • Biliary Cancer • Cholangiocarcinoma • Infectious Disease • Oncology • Septic Shock • Solid Tumor

Gut microbiota-associated immunomodulation contributes to the protective effects of fluvastatin against endometriosis in a mouse model, accompanied by increased Akkermansia muciniphila abundance. (PubMed, Front Microbiol) - "Gut microbiota may contribute to the beneficial effects of fluvastatin in EMs. These results support the potential value of microbiota-informed therapeutic strategies for EMs."

Journal • Preclinical • Endometriosis • Gynecology • Immunology • Oncology • Transplantation • Women's Health

Comparison chart: Statins. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Redirecting Cholesterol Metabolism During Ex Vivo Biomanufacturing Enhances the Metabolic Fitness and Antitumor Efficacy of CAR-T Cells. (PubMed, Int J Biol Sci) - "We investigated the effects of cholesterol modulation during ex vivo CAR-T cell expansion by using low-dose fluvastatin (FL), a clinically approved HMG-CoA reductase inhibitor...Inhibiting ERK1/2 or ATP synthesis abrogates these benefits, indicating that ERK1/2-dependent mitochondrial metabolism is required for CAR-T cell functional improvements conferred by FL. These findings establish cholesterol metabolism as a tunable axis during CAR-T cell manufacturing and propose a clinically feasible, GMP-compatible strategy to enhance CAR-T cell fitness and therapeutic efficacy."

Journal • Preclinical • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor

Does Ras/Rho Have Skin in the Game: The Importance of the Isoprenoid Biosynthesis Pathway in Merkel Cell Carcinoma Cell Lines. (PubMed, Cancers (Basel)) - "Our findings demonstrate varying dependence on the IBP between viral-positive and viral-negative MCC and highlight the importance of cellular dynamics when determining a treatment regimen for patients with MCC."

Journal • Preclinical • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor

Disruption of upstream ox-LDL signaling and HSP90-mediated NLRP3 stability protects against experimental steatohepatitis. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This study investigated the therapeutic potential of combining alvespimycin (ALV), an HSP90 inhibitor, with fluvastatin (FLU), a lipid-lowering agent, in a thioacetamide (TAA)-augmented high-fat diet rat model of MASH, hereafter referred to as the NASH model in keeping with established preclinical nomenclature...Collectively, these findings suggest that ALV + FLU may represent a mechanistically rational, multitarget strategy capable of attenuating several hallmarks of MASH pathogenesis. Further studies are warranted to evaluate the translational potential of this combinatorial regimen for MASLD/MASH management."

Journal • Dyslipidemia • Fibrosis • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • CDC37 • HSP90AA1 • IL18 • IL1B • NLRP3 • SMAD2 • TGFB1 • TNFA